Latest news
11-07-2023 - New £2.5 Million LifeArc/EB Res-Net Call: Repurposing Therapies For Epidermolysis Bullosa (EB)
Project grants of up to £1 million for projects to repurpose existing therapeutics to treat chronic inflammation, fibrosis and skin cancer initiation in Epidermolysis Bullosa.
DEBRA Austria (a member of EB-ResNet) and LifeArc are co-funding a Special Joint Call - Repurposing Therapies for EB - to develop therapeutics for severe unmet needs with potential for rapid clinical translation to benefit Epidermolysis Bullosa (EB) patients. The Call focuses on repurposing or repositioning existing therapeutics to treat chronic inflammation (CIF) and non-healing wounds, and the consequent fibrosis and skin cancer initiation in severe disease subtypes, which have been identified as a significant unmet need for people with EB.
[...]